首页> 外文期刊>Arthritis Research >Classification and characteristics of Japanese patients with antineutrophil cytoplasmic antibody-associated vasculitis in a nationwide, prospective, inception cohort study
【24h】

Classification and characteristics of Japanese patients with antineutrophil cytoplasmic antibody-associated vasculitis in a nationwide, prospective, inception cohort study

机译:在全国性前瞻性队列研究中,日本抗中性粒细胞胞浆抗体相关血管炎患者的分类和特征

获取原文
           

摘要

Introduction We investigated the clinical and serological features of patients with antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV) in Japan using data from a nationwide, prospective, inception cohort study. Methods In total, 156 Japanese patients with newly diagnosed AAV were classified according to the European Medicines Agency (EMEA) algorithm with exploratory surrogate markers for AAV-related non-granulomatous pulmonary lesions, predefined as alveolar haemorrhage and interstitial lung disease (ILD), and their clinical and serological features were evaluated. Results Using the EMEA algorithm, we identified 14 patients (9.0%) with eosinophilic granulomatosis with polyangiitis (EGPA), 33 (21.2%) with granulomatosis with polyangiitis (GPA), 78 (50.0%) with microscopic polyangiitis and renal-limited vasculitis (MPA/RLV), and 31 (19.9%) with unclassifiable vasculitis. The average ages of patients with EGPA (male/female, 5/9), GPA (12/21), and MPA/RLV (35/43) and unclassifiable (9/22) were 58.0, 63.6, 71.1, and 70.6?years, respectively. Myeloperoxidase (MPO)-ANCA and proteinase-3 ANCA positivity was 50.0% and 0% for EGPA, 54.6% and 45.5% for GPA, 97.4% and 2.6% for MPA/RLV, and 93.5% and 3.2% for unclassifiable, respectively. According to the Birmingham Vasculitis Activity Score (BVAS), cutaneous (71.4%) and nervous system (92.9%) manifestations were prominent in EGPA and ear, nose, and throat manifestations (84.9%) and chest manifestations (66.7%) in GPA. Renal manifestations developed frequently in MPA/RLV (91.0%) and GPA (63.6%). The average serum creatinine levels were 0.71?mg/dL for EGPA, 1.51?mg/dL for GPA, 2.46?mg/dL for MPA/RLV, and 0.69?mg/dL for unclassifiable. The percentages of patients with ILD were 14.3% for EGPA, 9.0% for GPA, 47.4% for MPA/RLV, and 61.3% for unclassifiable. Patients with ILD ( n =?61) had significantly lower BVAS ( P =?0.019) with fewer ear, nose, and throat and cardiovascular manifestations than patients without ILD ( n =?95). Conclusions MPO-ANCA-positive MPA/RLV is the most common form of AAV in Japanese patients, and one-half of patients with GPA were positive for MPO-ANCA. ILD is an important clinical manifestation in Japanese patients with AAV. Unclassifiable vasculitis with MPO-ANCA positivity and ILD may represent a novel variant of MPA. Trial Registration The University Hospital Medical Information Network Clinical Trials Registry: UMIN000001648 . Registered 28 February 2009.
机译:简介我们使用来自全国范围的前瞻性队列研究的数据,调查了日本抗中性粒细胞胞浆抗体(ANCA)相关血管炎(AAV)患者的临床和血清学特征。方法根据欧洲药物管理局(EMEA)算法,对156例日本新诊断的AAV患者进行了分类,使用探索性替代标志物针对AAV相关的非肉芽肿性肺部病变定义为肺泡出血和间质性肺病(ILD),以及他们的临床和血清学特征进行了评估。结果使用EMEA算法,我们确定了14例(9.0%)嗜酸性肉芽肿合并多血管炎(EGPA),33例(21.2%)肉芽肿合并多血管炎(GPA),78例(50.0%)显微镜下多发性血管炎和肾限制性血管炎( MPA / RLV)和31例(19.9%)患有无法分类的血管炎。 EGPA(男性/女性,5/9),GPA(12/21),MPA / RLV(35/43)和无法分类(9/22)的患者的平均年龄为58.0、63.6、71.1和70.6?年。髓过氧化物酶(MPO)-ANCA和蛋白酶3 ANCA的阳性率分别为EGPA的50.0%和0%,GPA的54.6%和45.5%,MPA / RLV的97.4%和2.6%,无法分类的93.5%和3.2%。根据伯明翰血管炎活性评分(BVAS),皮肤(71.4%)和神经系统(92.9%)的表现在EGPA中很明显,耳,鼻,喉的表现(84.9%)和胸腔的表现(66.7%)在GPA中很明显。肾表现在MPA / RLV(91.0%)和GPA(63.6%)中频繁发生。血清平均肌酐水平对于EGPA为0.71?mg / dL,对于GPA为1.51?mg / dL,对于MPA / RLV为2.46?mg / dL,对于无法分类为0.69?mg / dL。 ILD患者中EGPA的百分比为14.3%,GPA的百分比为9.0%,MPA / RLV的百分比为47.4%,无法分类的百分比为61.3%。与没有ILD的患者相比,患有ILD的患者(n =?61)的BVAS显着降低(P =?0.019),耳,鼻,喉咙和心血管疾病的表现更少。结论MPO-ANCA阳性MPA / RLV是日本患者最常见的AAV形式,一半的GPA患者MPO-ANCA阳性。 ILD是日本AAV患者的重要临床表现。具有MPO-ANCA阳性和ILD的无法分类的血管炎可能代表了MPA的一种新型变异。试验注册大学医院医学信息网络临床试验注册中心:UMIN000001648。 2009年2月28日注册。

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号